Evidence map›Paper›PMID 31558165›Full record

ArticleCancer communications (London, England)2019

Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience.

Qian Zhao, Feng Li, Ping Song, Xiaogang Zhou, Zhiming An, Jiangang Mei, Jingjing Shao, Hanqing Li, Xuli Wang, Xing Guo and 1 more

Abstract readLetter
In one paragraph

Article in Cancer communications (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Amyloidosis: a case series and review of the literature.Journal of medical case reports · 2023
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qian ZhaoDepartment of Hematology, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Xuanwu District, Nanjing, 210002, Jiangsu, P. R. China.
Feng LiDepartment of Hematology, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Xuanwu District, Nanjing, 210002, Jiangsu, P. R. China.
Ping SongDepartment of Hematology, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Xuanwu District, Nanjing, 210002, Jiangsu, P. R. China.
Xiaogang ZhouDepartment of Hematology, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Xuanwu District, Nanjing, 210002, Jiangsu, P. R. China.
Zhiming AnDepartment of Hematology, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Xuanwu District, Nanjing, 210002, Jiangsu, P. R. China.
Jiangang MeiDepartment of Hematology, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Xuanwu District, Nanjing, 210002, Jiangsu, P. R. China.
Jingjing ShaoDepartment of Hematology, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Xuanwu District, Nanjing, 210002, Jiangsu, P. R. China.
Hanqing LiDepartment of Hematology, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Xuanwu District, Nanjing, 210002, Jiangsu, P. R. China.
Xuli WangDepartment of Hematology, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Xuanwu District, Nanjing, 210002, Jiangsu, P. R. China.
Xing GuoDepartment of Hematology, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Xuanwu District, Nanjing, 210002, Jiangsu, P. R. China.
Yongping ZhaiDepartment of Hematology, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Xuanwu District, Nanjing, 210002, Jiangsu, P. R. China. zhaiyongping00@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immunoglobulin DAdultAgedAged, 80 and overAntineoplastic AgentsBortezomibFemaleHumansLenalidomideMaleMiddle AgedMultiple MyelomaRisk FactorsSurvival AnalysisThalidomideTreatment OutcomeAntineoplastic AgentsBortezomibImmunoglobulin DLenalidomideThalidomide

Identifiers

PMID31558165
PMCPMC6764140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.